WO2021210924A1 - 아프리카돼지열병 백신 조성물 - Google Patents
아프리카돼지열병 백신 조성물 Download PDFInfo
- Publication number
- WO2021210924A1 WO2021210924A1 PCT/KR2021/004724 KR2021004724W WO2021210924A1 WO 2021210924 A1 WO2021210924 A1 WO 2021210924A1 KR 2021004724 W KR2021004724 W KR 2021004724W WO 2021210924 A1 WO2021210924 A1 WO 2021210924A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genbank accession
- seq
- sequence
- swine fever
- african swine
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/187—Hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to polypeptides, polynucleotides, plasmids and vaccine compositions containing them involved in generating an immune response against African swine fever.
- the present invention also relates to a method of generating an immune response against African swine fever in a subject.
- the present invention relates to polypeptides, polynucleotides, and plasmids involved in generating an immune response against African swine fever, and pharmaceutical compositions for treating or preventing African swine fever containing them.
- the present invention also relates to a method for preventing or treating African swine fever in a subject.
- African Swine Fever is a deadly viral hemorrhagic swine epidemic. Once onset, it is highly contagious, there is no cure, and the mortality rate of most infected pigs is very high. . Therefore, when African swine fever occurs, it must be reported immediately to the World Organization for Animal Health (OIE), and international trade related to pigs is immediately halted. African swine fever is classified as a very important disease by the World Organization for Animal Health (OIE), and in Korea, it has been designated and managed as a type 1 legal infectious disease under the Livestock Infectious Diseases Prevention Act.
- OIE World Organization for Animal Health
- African swine fever virus is a DNA virus with a diameter of about 200 nm, belonging to the genus Asfivirus of the Asfarviridae family. African swine fever virus does not infect humans or other animals, but is reported to infect only animals belonging to the Suidae family.
- African swine fever virus is present in large quantities in saliva, respiratory secretions, urine, and feces from infected animals, and African swine fever is transmitted to normal animals that come into contact with these substances. Because the virus can persist in blood and tissues after pig death, feeding pigs with untreated remains containing tissues from infected animals can spread rapidly. Alternatively, the virus can be transmitted through blood spilled during a fight between pigs, or diarrhea mixed with blood. Alternatively, bloodsucking insects such as soft ticks, mosquitoes, and biting flies belonging to Ornithodoros spp. may carry the African swine fever virus and act as a medium for disease transmission when biting or sucking pigs. .
- African swine fever can infect pigs of any age. Morbidity depends on the virus infected and the route of exposure, and the incubation period for natural infection varies from 4 to 19 days. The mortality rate is almost 100% when infected with highly pathogenic viruses.
- African swine fever virus can be classified into high pathogenicity, moderate pathogenicity and low pathogenicity according to pathogenicity. Highly pathogenic African swine fever virus usually causes acute (pigs die 1-4 days after infection) and acute (pigs die 3-8 days after infection) diseases, while highly pathogenic African swine fever virus causes acute (infection 11-) Pigs die after 15 days) and subacute (pigs die after 20 days of infection) diseases. Low pathogenic ASF virus has been reported only in endemic areas and causes subclinical or chronic disease.
- African swine fever Diagnosis of African swine fever is difficult at an early stage, especially when the number of affected pigs is small. The reason is that the clinical symptoms of African swine fever are confused with other hemorrhagic swine diseases such as septicaemic salmonellosis and porcine dermatitis nephropathy syndrome (PDNS). Accurate discrimination is possible only through laboratory diagnosis, such as the method of detecting the virus in blood and internal organs, and the method of detecting antibodies in the serum of infected pigs. many. For example, in China, ASF is so contagious that African swine fever has occurred in all administrative regions of China in less than nine months after the first ASF was identified in 2018.
- PDNS porcine dermatitis nephropathy syndrome
- African swine fever virus has 10 to 12 proteins, African swine fever virus has more than 150 proteins and the virus types (24 genotypes) are diverse. Therefore, experts have predicted that it will be difficult to commercialize a vaccine within the next 10 years.
- One object of the present invention is to provide a polypeptide capable of generating an immune response against African swine fever and a polynucleotide encoding the same.
- Another object of the present invention is to provide a plasmid capable of generating an immune response against African swine fever.
- Another object of the present invention is to provide a vaccine composition for African swine fever.
- Another object of the present invention is to provide a method for generating an immune response against African swine fever in a subject.
- Another object of the present invention is to provide a pharmaceutical composition for the treatment or prevention of African swine fever in a subject.
- Another object of the present invention is to provide a method for treating or preventing African swine fever in a subject.
- one aspect of the present invention is a polypeptide comprising the amino acid sequence of one or more of the African swine fever virus genes p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R and K205R provides
- Another aspect of the present invention provides a polypeptide comprising at least one of the amino acid sequence of SEQ ID NOs: 1 to 10 or an amino acid sequence having at least 90% homology thereto.
- homology refers to the degree of correspondence with a given polypeptide sequence or polynucleotide sequence and can be expressed as a percentage.
- homologous sequences having the same or similar activity to a given polypeptide sequence are expressed as "% homology".
- the homology is, for example, using standard software that calculates parameters such as score, identity and similarity, for example, BLAST 2.0, or hybridization written under defined stringent conditions. It can be confirmed by comparing the sequences experimentally, and an appropriate hybridization condition defined can be determined by a method well known to those skilled in the art.
- amino acid sequences of SEQ ID NOs: 1 to 10 are, respectively, from various strains of African swine fever virus genes p30 (CP204L), p54 (E183L), C-type lectin (EP153R), CD2v (EP402R), p49 (B438L) , pp62 (CP530R), EP364R, F317L, A104R, is a consensus sequence derived by comparing the sequence homology of K205R.
- polypeptide comprising at least one of the amino acid sequence of SEQ ID NOs: 1 to 10 or an amino acid sequence having 90% or more homology thereto can effectively act as an antigen capable of generating an immune response against African swine fever.
- the polypeptide may include one of the above amino acid sequences, or may include two or more.
- the polypeptide may further include a Kozak sequence, an IgE leader sequence, a ubiquitin sequence and/or a cleavage site sequence.
- the polypeptide may consist of the amino acid sequence of Kozak sequence - IgE leader sequence - SEQ ID NO: 1.
- the polypeptide may be composed of a Kozak sequence - an IgE leader sequence - a ubiquitin sequence - the amino acid sequence of SEQ ID NO: 1.
- the polypeptide may consist of a Kozak sequence - an IgE leader sequence - a ubiquitin sequence - an amino acid sequence of SEQ ID NO: 1 - a cleavage site sequence - an amino acid sequence of SEQ ID NO: 2.
- the ubiquitin sequence may preferably be SEQ ID NO: 41
- the cleavage site sequence may preferably be SEQ ID NO: 43.
- One aspect of the present invention provides a polynucleotide comprising at least one nucleotide sequence of the African swine fever virus genes p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R and K205R.
- Another aspect of the present invention provides a polynucleotide comprising at least one of the nucleotide sequences of SEQ ID NOs: 11 to 20 or nucleotide sequences having 90% or more homology thereto.
- another aspect of the present invention provides a polynucleotide encoding at least one of the amino acid sequence of SEQ ID NOs: 1 to 10 or an amino acid sequence having 90% or more homology thereto.
- the polynucleotide encoding the amino acid sequence of SEQ ID NOs: 1 to 10 may be the nucleotide sequences of SEQ ID NOs: 11 to 20, respectively.
- the nucleotide sequences of SEQ ID NOs: 11 to 20 are, respectively, from various strains of African swine fever virus, genes p30 (CP204L), p54 (E183L), C-type lectin (EP153R), CD2v (EP402R), p49 (B438L) , pp62 (CP530R), EP364R, F317L, A104R, is a consensus sequence derived by comparing the sequence homology of K205R.
- the polynucleotide may be one in which the amino acid sequence of SEQ ID NOs: 1 to 10 or the nucleotide sequence of SEQ ID NOs: 11 to 20 is changed to a codon optimized for a subject to generate an immune response.
- the subject is, for example, an animal.
- the animal may be, for example, a mammal, including pigs, cattle, horses, sheep, goats, deer, humans, and the like.
- the animal is a pig.
- the polynucleotide may include one of the nucleotide sequences, or may include two or more.
- the polynucleotide may further include a Kozak sequence, an IgE leader sequence, a ubiquitin sequence, and/or a cleavage site sequence.
- the polynucleotide may be composed of a Kozak sequence - an IgE leader sequence - a nucleotide sequence of SEQ ID NO: 11.
- the polynucleotide may be composed of a Kozak sequence - an IgE leader sequence - a ubiquitin sequence - the nucleotide sequence of SEQ ID NO: 11.
- the polynucleotide may be composed of a Kozak sequence - an IgE leader sequence - a ubiquitin sequence - a nucleotide sequence of SEQ ID NO: 11 - a cleavage site sequence - a nucleotide sequence of SEQ ID NO: 12.
- the ubiquitin sequence may preferably be SEQ ID NO: 42
- the cleavage site sequence may preferably be SEQ ID NO: 44.
- One aspect of the present invention provides a plasmid comprising a polynucleotide comprising at least one nucleotide sequence of the African swine fever virus genes p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R and K205R. do.
- Another aspect of the present invention provides a plasmid comprising a polynucleotide comprising at least one of the nucleotide sequences of SEQ ID NOs: 11 to 20 or nucleotide sequences having 90% or more homology thereto.
- Another aspect of the present invention provides a plasmid comprising a polynucleotide encoding at least one of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% homology with the sequence of SEQ ID NO: 1.
- plasmid refers to a DNA preparation containing a DNA sequence operably linked to suitable regulatory sequences capable of expressing the DNA in a suitable host or subject.
- the plasmid may be a vector, a phage particle, or simply a potential genomic insert.
- a plasmid may be used interchangeably herein with a vector (or viral vector).
- the plasmid may be prepared according to a conventional method known in the art. For example, by inserting the polynucleotide into a plasmid vector through gene cloning, the plasmid according to the present invention can be prepared and used as a DNA vaccine.
- the plasmid may contain one of the polynucleotides, or may contain two or more.
- the polynucleotide may further include a Kozak sequence, an IgE leader sequence, a ubiquitin sequence, and/or a cleavage site sequence.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 31, wherein SEQ ID NO: 31 is one in which the nucleotide sequences of SEQ ID NOs: 11 to 20 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 36, wherein SEQ ID NO: 36 is a ubiquitin sequence and the nucleotide sequence of SEQ ID NOs: 11 to 20 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 50, wherein SEQ ID NO: 50 is a ubiquitin sequence and the nucleotide sequence of SEQ ID NOs: 11 to 20 are sequentially linked, the SEQ ID NO: 11 Each of the nucleotide sequences of to 20 is sequentially linked with a cleavage site sequence.
- the ubiquitin sequence may preferably be the nucleotide sequence of SEQ ID NO: 42.
- CD8 + T cells recognize MHC class I-associated peptides derived from endogenous antigens such as viral antigens or oncogene products located in the cytosol. Prior to antigen presentation of these MHC class I molecules, the antigen is ubiquitinated and processed into antigenic peptides by the proteasome. Therefore, ubiquitin-fused proteins enter the proteasome dependent degradation pathway and enhance the ability to present MHC class I peptides, thereby inducing a cellular immune response (CTL, Cytotoxic T Lymphocyte response). can increase
- the cleavage site sequence may preferably be the nucleotide sequence of SEQ ID NO: 44.
- the cleavage site refers to a peptide that is recognized and cleaved by a protease.
- the polypeptide expressed from the plasmid containing the polynucleotide can be cleaved by a degrading enzyme, and each cleaved polypeptide can effectively act as an antigen capable of generating an immune response against African swine fever.
- the cleavage site may be cleaved by an endogenous enzyme present in a cell, and specifically cleaved by a furine protease, but is not limited thereto.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 32, wherein SEQ ID NO: 32 is one in which the nucleotide sequences of SEQ ID NOs: 11 to 14 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 37, wherein SEQ ID NO: 37 is a ubiquitin sequence and the nucleotide sequence of SEQ ID NOs: 11 to 14 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 33, wherein SEQ ID NO: 33 is one in which the nucleotide sequences of SEQ ID NOs: 15 to 20 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 38, wherein SEQ ID NO: 38 is a ubiquitin sequence and the nucleotide sequence of SEQ ID NOs: 15 to 20 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 34, wherein the nucleotide sequence of SEQ ID NO: 11, 12, 16, 13 and 14 is sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 39, wherein SEQ ID NO: 39 is a ubiquitin sequence and the nucleotide sequences of SEQ ID NOs: 11, 12, 16, 13 and 14 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 35, wherein the nucleotide sequence of SEQ ID NO: 15, 17, 18, 19 and 20 is sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 40, wherein SEQ ID NO: 40 is a ubiquitin sequence and the nucleotide sequences of SEQ ID NOs: 15, 17, 18, 19 and 20 are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 50, wherein SEQ ID NO: 50 is a ubiquitin sequence of SEQ ID NO: 42; and SEQ ID NO: 11, 44, 12, 44, 13, 44, 14, 44, 15, 44, 16, 44, 17, 44, 18, 44, 19, 44, 20 nucleotide sequences are sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 51, wherein SEQ ID NO: 51 is a ubiquitin sequence of SEQ ID NO: 42; And the nucleotide sequence of SEQ ID NO: 11, 44, 12, 44, 13, 44, 14, including the cleavage site sequence of SEQ ID NO: 44, is sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 52, wherein SEQ ID NO: 52 is a ubiquitin sequence of SEQ ID NO: 42; And the nucleotide sequence of SEQ ID NO: 15, 44, 16, 44, 17, 44, 18, 44, 19, 44, 20, including the cleavage site sequence of SEQ ID NO: 44, is sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 53, wherein SEQ ID NO: 53 is a ubiquitin sequence of SEQ ID NO: 42; And the nucleotide sequence of SEQ ID NO: 11, 44, 12, 44, 16, 44, 13, 44, 14, including the cleavage site sequence of SEQ ID NO: 44, is sequentially linked.
- the plasmid may include the nucleotide sequence of SEQ ID NO: 54, wherein SEQ ID NO: 54 is a ubiquitin sequence of SEQ ID NO: 42; And the nucleotide sequence of SEQ ID NO: 15, 44, 17, 44, 18, 44, 19, 44, 20, including the cleavage site sequence of SEQ ID NO: 44, is sequentially linked.
- Another aspect of the present invention provides an African swine fever vaccine composition
- a polypeptide of the present invention a polynucleotide of the present invention, or a plasmid of the present invention.
- the polypeptide, the polynucleotide, and the plasmid are as described above unless otherwise specified.
- vaccine refers to an immunogenic or antigenic substance that produces immunity by administering, for example, injecting or oral administration, to a human or animal for the prevention of a disease as a biological agent containing an antigen that gives immunity to an individual.
- the vaccine may be a DNA vaccine.
- DNA vaccine refers to a vaccine that induces an immune response by artificially replicating some of genes such as pathogens or viruses and then administering them. These DNA vaccines have various advantages compared to the existing protein vaccines: i) There is no need to directly handle dangerous pathogens because they can be synthesized only with the genetic information of the pure target pathogen antigen, ii) only some of the genes necessary for inducing toxicity Because it is used, there is no fear of showing any particular toxicity even when administered to an administration body, and iii) it is possible to develop a vaccine by responding quickly to various infectious diseases that occur suddenly because of its simplicity consisting of only plasmid DNA.
- the African swine fever vaccine composition may preferably have protective immunity against the African swine fever virus.
- the vaccine composition of the present invention may include a veterinarily acceptable carrier.
- veterinary acceptable carrier includes any and all solvents, dispersion media, coatings, adjuvants, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
- Carriers, excipients, and diluents that may be included in the vaccine composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, glycerin, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- the vaccine composition of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like and sterile injection solutions according to conventional methods, respectively.
- oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like and sterile injection solutions according to conventional methods, respectively.
- it can be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- poly-L-Glutamic acid can be used to help in stabilization.
- the vaccine composition may be injected into a subject in various forms.
- injection may be performed by any one method selected from the group consisting of subcutaneous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, nasal administration, oral administration, transdermal administration and oral administration.
- the vaccine composition may include one or more adjuvants and the like to improve or enhance an immune response.
- Suitable adjuvants include peptides, aluminum hydroxide, aluminum phosphate, aluminum oxide, and compositions consisting of mineral or vegetable oils such as Marcol 52 and one or more emulsifiers or surface active substances such as resorcecithin, polyvalent cations, polyanions, and the like.
- One aspect of the present invention provides a method for generating an immune response against African swine fever virus in an individual, comprising administering the vaccine composition of the present invention to the individual.
- the vaccine composition is as described above unless otherwise specified.
- immune response refers to the activation of a host's immune system in response to introduction of an antigen.
- the immune response may be in the form of a cellular response or a humoral response, or both.
- the term “individual” refers to animals, including humans, and may be, for example, mammals, more specifically, pigs, cattle, horses, sheep, goats, deer, humans, and the like. Preferably, it is a pig.
- the term “individual” may be used interchangeably with subject or host.
- the vaccine composition of the present invention may include an effective amount of an active ingredient, ie, a whole recombinant polypeptide, a recombinant polynucleotide, or a plasmid comprising the same together with a pharmaceutically acceptable carrier and adjuvant.
- an effective amount means that a component of a vaccine is in an amount sufficient to induce a specific immune response against the African swine fever virus in the vaccinated animal.
- An effective amount can be readily determined by one skilled in the art, for example, through routine experimentation in animals.
- the administration may be administered by any route suitable for administration of the DNA vaccine, for example, by subcutaneous, intramuscular, intraperitoneal or intravenous injection.
- Another aspect of the present invention provides a method for treating or preventing African swine fever in a subject, comprising administering to the subject a vaccine composition, polypeptide, polynucleotide or plasmid of the present invention.
- Another aspect of the present invention provides a pharmaceutical composition for treating or preventing African swine fever comprising the polypeptide, polynucleotide or plasmid according to the present invention.
- each term has the same meaning as described above unless otherwise specified.
- prevention refers to any action in which African swine fever is suppressed or delayed by administration of the composition according to the present invention.
- treatment used in the present invention refers to any action in which symptoms of African swine fever are improved, cured, ameliorated, or partially treated by administration of the composition according to the present invention.
- the vaccine composition according to the present invention is a DNA vaccine and has excellent protective immunity against African swine fever virus.
- the vaccine composition according to the present invention is very effective in inducing a cellular immune response against African swine fever.
- ASF 1 is a cleavage map of a vector containing an African Swine Fever (ASF) virus gene, a Kozak sequence, an IgE leader sequence, a ubiquitin sequence, and a furin cleavage site sequence. It relates to a vector comprising p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R and K205R as ASF virus genes.
- ASF African Swine Fever
- FIG. 2 is a cleavage map of a vector containing an ASF virus gene, including a Kozak sequence, an IgE leader sequence, a ubiquitin sequence, and a purine cleavage site sequence, and p30, p54, C-type lectin and CD2v as ASF virus genes. It's about vectors.
- FIG. 3 is a cleavage map of a vector containing an ASF virus gene, including a Kozak sequence, an IgE leader sequence, a ubiquitin sequence and a purine cleavage site sequence, and p49, pp62, EP364R, F317L, A104R and K205R as ASF virus genes. It's about a vector.
- cleavage map of a vector containing an ASF virus gene including a Kozak sequence, an IgE leader sequence, a ubiquitin sequence and a purine cleavage site sequence, and p30, p54, pp62, C-type lectin and CD2v as ASF virus genes. It relates to the containing vector.
- FIG. 5 is a cleavage map of a vector containing an ASF virus gene, a vector containing a Kozak sequence, an IgE leader sequence, a ubiquitin sequence and a purine cleavage site sequence, and p49, EP364R, F317L, A104R and K205R as ASF virus genes. is about
- FIG. 6 is a graph showing the number of cytotoxic T cells (CD8 + T cells) produced by ASF virus antigens (p30, p54 or CD2v) after DNA vaccination comprising an ASF virus gene, wherein the DNA vaccine Indicates the level of the induced cellular immune response.
- 'Mock' is the control group administered with the DNA vaccine that does not contain the ASF virus gene
- 'ASF_4G' is the experimental group that contains the ASF virus gene (p30, p54, C type lectin and CD2v) and is administered with the DNA vaccine that does not contain ubiquitin.
- 1, 'ASF_Ubi_4G' refers to Experimental Group 2, which includes ASF virus genes (p30, p54, C type lectin and CD2v) and is administered with a DNA vaccine containing ubiquitin.
- FIG. 7 is a graph showing the survival rate of pigs infected with ASF virus after DNA vaccination containing an ASF virus gene.
- 'Mock' refers to the control group administered with the DNA vaccine that does not contain the ASF virus gene
- 'ASF_Ubi_10G' refers to the ASF virus gene (p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R and K205R). and refers to the experimental group to which the DNA vaccine containing ubiquitin was administered.
- the amino acid sequence of SEQ ID NO: 1 and the nucleotide sequence of SEQ ID NO: 11 are consensus sequences derived by comparing the sequence homology of the p30 (CP204L) gene from various strains of African swine fever virus.
- the amino acid sequence of SEQ ID NO: 1 and the nucleotide sequence of SEQ ID NO: 11 are African swine fever virus strain ANG/70 (GenBank accession no. EU874271), Malawi/1978 (GenBank accession no. JQ744998), NAM/1/80 ( GenBank accession no. JQ745005), Dedza (GenBank accession no. JQ745028), BUR/90/1 (GenBank accession no.
- KC867500 MOZ/1979 (GenBank accession no. EU874310), SPEC/154 (GenBank accession no. EU874291), SPEC/205 (GenBank accession no. KC867500). EU874305), SPEC/209 (GenBank accession no. EU874290), SPEC/257 (GenBank accession no. EU874265), MOZ/94/8 (GenBank accession no. EU874276), E70 (GenBank accession no. AF462272), ZAM/2017 /Mbala/1 (GenBank accession no. LC322014), CN201801 (GenBank accession no. MH735141), DB/HLJ/2018 (GenBank accession no. MK333184), M-78 (GenBank accession no.
- the amino acid sequence of SEQ ID NO: 2 and the nucleotide sequence of SEQ ID NO: 12 are consensus sequences derived by comparing the sequence homology of the p54 (E183L) gene from various strains of African swine fever virus.
- the amino acid sequence of SEQ ID NO: 2 and the nucleotide sequence of SEQ ID NO: 12 are African swine fever virus strains Tengani/60 (GenBank accession no. KF015886), ANG/70 (GenBank accession no. EU874327), BA71 (GenBank accession no. KP055815), Malawi/1978 (GenBank accession no. KC662380), Brazil/79 (GenBank accession no.
- KF736414 LIL 90/1 (GenBank accession) No. KF736416), LIV 9/31 (GenBank accession no. KF015928), MAN 89/2 (GenBank accession no. KF015940), MOZ 2001/1 (GenBank accession no. KF736428), MPO 89/1 (GenBank accession no. KF015940). KF736418), Trench (GenBank accession no. KF736420), MOZ/1960 (GenBank accession no. KF736420). EU874371), Lillie (GenBank accession no. EU874341), Madagascar (GenBank accession no. KC662387), ZIM/92/1 (GenBank accession no.
- EU874345 SPEC/205 (GenBank accession no. EU874329), Co62 (GenBank accession no. FJ174387), E70 (GenBank accession no. FJ174389), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), Hu90 (GenBank accession no. FJ174399), SS81 (GenBank accession no. FJ174403), Ori90 (GenBank accession no. FJ174407), Nu98 .8B (GenBank accession no. FJ174418), OURT 88/3 (GenBank accession no. AM712240), Almodovar 99 (GenBank accession no.
- HQ645949 TAN/08/Mazim bu* (GenBank accession no. GQ410767), TAN/08/Mabibo* (GenBank accession no. GQ410768), Arm07 (GenBank accession no. JX857494), Az08D (GenBank accession no. JX857501), Oren08 (GenBank accession no. JX857498), Rostov09 (GenBank accession no. JX857494). JX857504), Tver0312/Novo (GenBank accession no. KJ627190), Bel13/Grodno (GenBank accession no. KJ627192), LT14/1490 (GenBank accession no. KJ627193), ETH/1 (GenBank accession no.
- MK333181 Pig/HLJ/2018 (GenBank accession no. MK333180), ASFV-SY18 (GenBank accession no. MH766894), CN201801 (GenBank accession no. MH735140), Estonia 2014 (GenBank) accession no. LS478113) and Nig6_JS10 (GenBank accession no. KT961344) were prepared by comparing the sequence homology of the p54 (E183L) gene.
- the amino acid sequence of SEQ ID NO: 3 and the nucleotide sequence of SEQ ID NO: 13 are consensus sequences derived by comparing the sequence homology of the C-type lectin (EP153R) gene from various strains of African swine fever virus.
- the amino acid sequence of SEQ ID NO: 3 and the nucleotide sequence of SEQ ID NO: 13 are African swine fever virus strain Katanga/63 (GenBank accession no. KM609340), Kenya (GenBank accession no. KM609361), BA71 (GenBank accession no. KP055815) , Davis (GenBank accession no. KM609336), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no.
- AF017034 K1 (GenBank accession no. AF017033), CR3 (GenBank accession no. AF017029), CR1 (GenBank accession no. AF017028), LC-PP (GenBank accession no. KM609345), Magadi (GenBank accession) no. kM609348), Bartlett (GenBank accession no. KM609335), Volgograd_2012/wb (GenBank accession no. KM609363), Volgograd_2012/dom (GenBank accession no. KM609) 362), Tver_2012/wb (GenBank accession no. KM609360), Rhodesia (GenBank accession no.
- the amino acid sequence of SEQ ID NO: 4 and the nucleotide sequence of SEQ ID NO: 14 are consensus sequences derived by comparing the sequence homology of the CD2v (EP402R) gene from various strains of African swine fever virus. Specifically, the amino acid sequence of SEQ ID NO: 4 and the nucleotide sequence of SEQ ID NO: 14 are African swine fever virus strain China/2018/AnhuiXCGQ (GenBank accession no. MK128995), DB/LN/2018 (GenBank accession no. MK333181), Pig/ HLJ/2018 (GenBank accession no. MK333180), ASFV-SY18 (GenBank accession no. MH766894), Belgium 2018/1 (GenBank accession no.
- KM609388 TSP80 (GenBank accessi) on no. KM609359), K-49 (GenBank accession no. KM609339), KK-262 (GenBank accession no. KM609341), Spencer (GenBank accession no. KM609357), MK-200 (GenBank accession no. KM609347), 691/88 (GenBank) accession no. KM609334), F-32 (GenBank accession no. KM609337), O-77 (GenBank accession no. KM609350), P-60 (GenBank accession no. KM609351), PPA (GenBank accession no. KM609352), STP- 1 (GenBank accession no.
- KM609355 BA71 (GenBank accession no. KP055815), STP-1-79 (GenBank accession no. KM609384), Malta (GenBank accession no. KM609380), Yamba-74 (GenBank accession no. KM609391) , TKF (GenBank accession no. KM609387), Kimuele-6 (GenBank accession no. KM609375), E-70 (GenBank accession no. KM609369), Cuba-71 (GenBank accession no. KM609366), CU-80 (GenBank accession no. KM609365), Brazil-80 (GenBank accession no. KM609364), MNI-82 (GenBank accession no.
- KM609378 K-73 (Le Bray) (GenBank accession no. KM609370), Madeira (GenBank accession no. KM609379), Diamang (GenBank accession no. KM609367), L-50 (GenBank accession no. KM609343), L-57 (GenBank accession no. KM609344), Kikasa-77 (GenBank accession no. KM609371), and VL (GenBank accession no. KM609390) were constructed by comparing the sequence homology of the CD2v (EP402R) gene.
- the amino acid sequence of SEQ ID NO: 5 and the nucleotide sequence of SEQ ID NO: 15 are consensus sequences derived by comparing the sequence homology of the p49 (B438L) gene from various strains of African swine fever virus. Specifically, the amino acid sequence of SEQ ID NO: 5 and the nucleotide sequence of SEQ ID NO: 15 are African swine fever virus strain BA71 (GenBank accession no. KP055815), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), OURT 88/3 (GenBank accession no. AM712240), Georgia 2007 (GenBank accession no. FR682468), Ken05/Tk1 (GenBank accession no.
- the amino acid sequence of SEQ ID NO: 6 and the nucleotide sequence of SEQ ID NO: 16 are consensus sequences derived by comparing the sequence homology of the pp62 (CP530R) gene from various strains of African swine fever virus. Specifically, the amino acid sequence of SEQ ID NO: 6 and the nucleotide sequence of SEQ ID NO: 16 are African swine fever virus strain BA71 (GenBank accession no. KP055815), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), OURT 88/3 (GenBank accession no. AM712240), Georgia 2007 (GenBank accession no. FR682468), Ken05/Tk1 (GenBank accession no.
- the amino acid sequence of SEQ ID NO: 7 and the nucleotide sequence of SEQ ID NO: 17 are consensus sequences derived by comparing the sequence homology of the EP364R gene from various strains of African swine fever virus. Specifically, the amino acid sequence of SEQ ID NO: 7 and the nucleotide sequence of SEQ ID NO: 17 are African swine fever virus strain BA71 (GenBank accession no. KP055815), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), OURT 88/3 (GenBank accession no. AM712240), Georgia 2007 (GenBank accession no. FR682468), Ken05/Tk1 (GenBank accession no.
- the amino acid sequence of SEQ ID NO: 8 and the nucleotide sequence of SEQ ID NO: 18 are consensus sequences derived by comparing the sequence homology of the F317L gene from various strains of African swine fever virus. Specifically, the amino acid sequence of SEQ ID NO: 8 and the nucleotide sequence of SEQ ID NO: 18 are African swine fever virus strain BA71 (GenBank accession no. KP055815), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), OURT 88/3 (GenBank accession no. AM712240), Georgia 2007 (GenBank accession no. FR682468), Ken05/Tk1 (GenBank accession no.
- Pol16_20186_o7 (GenBank accession no. Pol_04461_o7 (GenBank accession no. Pol_04461_C) accession no. MG939588), Belgium 2018/1 (GenBank accession no. LR536725), China/2018/AnhuiXCGQ (GenBank accession no. MK128995), DB/LN/2018 (GenBank accession no. MK333181), Pig/HLJ/2018 ( Gen Bank access no. MK333180), ASFV-SY18 (GenBank accession no. MH766894) was prepared by comparing the sequence homology of the F317L gene.
- the amino acid sequence of SEQ ID NO: 9 and the nucleotide sequence of SEQ ID NO: 19 are consensus sequences derived by comparing the sequence homology of the A104R gene from various strains of African swine fever virus. Specifically, the amino acid sequence of SEQ ID NO: 9 and the nucleotide sequence of SEQ ID NO: 19 are African swine fever virus strain BA71 (GenBank accession no. KP055815), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), OURT 88/3 (GenBank accession no. AM712240), Georgia 2007 (GenBank accession no. FR682468), Ken05/Tk1 (GenBank accession no.
- the amino acid sequence of SEQ ID NO: 10 and the nucleotide sequence of SEQ ID NO: 20 are consensus sequences derived by comparing the sequence homology of the K205R gene from various strains of African swine fever virus.
- the amino acid sequence of SEQ ID NO: 10 and the nucleotide sequence of SEQ ID NO: 20 are African swine fever virus strain BA71 (GenBank accession no. KP055815), Ba71V (GenBank accession no. U18466), E75 (GenBank accession no. FN557520), OURT 88/3 (GenBank accession no. AM712240), Georgia 2007 (GenBank accession no. FR682468), Ken05/Tk1 (GenBank accession no.
- a vaccine was prepared using the African swine fever virus gene of Example 1.
- a DNA plasmid containing the gene, a Kozak sequence, an IgE leader sequence, a ubiquitin sequence, and/or a furin cleavage site sequence was prepared by a general method known in the art. Then, Escherichia coli having the DNA plasmid was inoculated into 2.5L of LB medium and cultured at 37°C, oil-in-water (O/W). A plasmid was extracted from the cultured E. coli using the EndoFree Plasmid Giga kit (QIAGEN, Cat#12391), and the extracted plasmid was used for subsequent inoculation as a vaccine.
- FIGS. 1 to 5 Cleavage maps of the prepared DNA plasmid are shown in FIGS. 1 to 5 .
- the spleen was extracted from the mouse a week later and splenocytes were isolated, and IFN-gamma ELISpot KIT (Cellular Technology Limited/USA) was used for the isolated splenocytes. and mouse IFN-gamma ELISpot analysis was performed. Specifically, by analyzing the number of cytotoxic T cells (CD8 + T cells) secreting IFN- ⁇ after treating the splenocytes administered with each vaccine with the polypeptide of each antigen gene, induced by virus infection after vaccination The degree of cellular immune response was confirmed.
- IFN-gamma ELISpot KIT Cellular Technology Limited/USA
- the DNA vaccine was administered to piglets a total of three times (week 0, week 2, week 4). After that, the African swine fever virus was challenged at the 7th week, and the survival rate for 28 days thereafter was investigated. At this time, the type of DNA vaccine administered to each control group and experimental group was set as follows.
- DNA vaccine containing African swine fever virus gene and ubiquitin (ASF_Ubi_10G DNA vaccine; ubiquitin, p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R and K205R)
- the DNA vaccine containing the African swine fever virus gene and ubiquitin when inoculated, it shows excellent viability even when infected with the African swine fever virus, so the DNA vaccine is useful as a vaccine composition for preventing African swine fever. found that it could be used.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
p30 | p54 | CD2v | |
대조군 (Mock) | 0.0 | 0.0 | 8.5 |
실험군 1 (ASF_4G) | 0.0 | 769.0 | 336.5 |
실험군 2 (ASF_Ubi_4G) | 23 | 1223.5 | 764 |
Claims (18)
- 아프리카돼지열병 바이러스의 유전자 p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R 및 K205R 중 하나 이상의 아미노산 서열을 포함하는 폴리펩티드.
- 제1항에 있어서,서열번호 1 내지 10의 아미노산 서열 또는 이와 90% 이상의 상동성을 갖는 아미노산 서열 중 하나 이상을 포함하는 폴리펩티드.
- 제1항에 있어서,Kozak 서열, IgE leader 서열, 유비퀴틴(ubiquitin) 서열 및 퓨린 절단 부위(Furin cleavage site) 서열 중 하나 이상을 더 포함하는 폴리펩티드.
- 제1항에 있어서,서열번호 41의 아미노산 서열을 더 포함하는 폴리펩티드.
- 제1항에 있어서,서열번호 43의 아미노산 서열을 더 포함하는 폴리펩티드.
- 아프리카돼지열병 바이러스의 유전자 p30, p54, C-type lectin, CD2v, p49, pp62, EP364R, F317L, A104R 및 K205R 중 하나 이상의 염기 서열을 포함하는 폴리뉴클레오티드.
- 제6항에 있어서,서열번호 1 내지 10의 아미노산 서열 또는 이와 90% 이상의 상동성을 갖는 아미노산 서열을 코딩하는 염기 서열, 또는 서열번호 11 내지 20의 염기 서열 또는 이와 90% 이상의 상동성을 갖는 염기 서열을 포함하는 폴리뉴클레오티드.
- 제6항에 있어서,Kozak 서열, IgE leader 서열, 유비퀴틴(ubiquitin) 서열 및 절단 부위(cleavage site) 서열 중 하나 이상을 더 포함하는 폴리뉴클레오티드.
- 제6항에 있어서,서열번호 42의 염기 서열을 더 포함하는 폴리뉴클레오티드.
- 제6항에 있어서,서열번호 44의 염기 서열을 더 포함하는 폴리뉴클레오티드.
- 제6항의 폴리뉴클레오티드를 포함하는 플라스미드.
- 제11항에 있어서,서열번호 31 내지 40, 및 서열번호 50 내지 54의 염기 서열 중 어느 하나를 포함하는 플라스미드.
- 제1항 내지 제5항 중 어느 한 항의 폴리펩티드, 제6항 내지 제10항 중 어느 항의 폴리뉴클레오티드, 또는 제11항 및 제12항 중 어느 한 항의 플라스미드를 포함하는, 아프리카돼지열병 백신 조성물.
- 제13항의 백신 조성물을 인간을 제외한 동물에게 투여하는 단계를 포함하는, 상기 동물에서 아프리카돼지열병 바이러스에 대한 면역 반응을 생성하는 방법.
- 제14항에 있어서,상기 투여는 전기천공(electroporation)에 의한 투여인 것을 특징으로 하는 방법.
- 제13항의 백신 조성물을 인간을 제외한 동물에게 투여하는 단계를 포함하는, 아프리카돼지열병을 치료 또는 예방하는 방법.
- 제16항에 있어서,상기 투여는 전기천공(electroporation)에 의한 투여인 것을 특징으로 하는 방법.
- 제1항 내지 제5항 중 어느 한 항의 폴리펩티드, 제6항 내지 제10항 중 어느 한 항의 폴리뉴클레오티드, 또는 제11항 및 제12항 중 어느 한 항의 플라스미드를 포함하는, 아프리카돼지열병 치료 또는 예방용 약학 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3181812A CA3181812A1 (en) | 2020-04-14 | 2021-04-14 | African swine fever vaccine composition |
MX2022012925A MX2022012925A (es) | 2020-04-14 | 2021-04-14 | Composición de vacuna contra la peste porcina africana. |
EP21788370.1A EP4137506A1 (en) | 2020-04-14 | 2021-04-14 | African swine fever vaccine composition |
JP2022562972A JP2023522053A (ja) | 2020-04-14 | 2021-04-14 | アフリカ豚熱病ワクチン組成物 |
BR112022020836A BR112022020836A2 (pt) | 2020-04-14 | 2021-04-14 | Composição da vacina da febre suína africana |
CN202180042721.7A CN115916803A (zh) | 2020-04-14 | 2021-04-14 | 非洲猪瘟疫苗组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200045271 | 2020-04-14 | ||
KR10-2020-0045271 | 2020-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021210924A1 true WO2021210924A1 (ko) | 2021-10-21 |
Family
ID=78085327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/004724 WO2021210924A1 (ko) | 2020-04-14 | 2021-04-14 | 아프리카돼지열병 백신 조성물 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4137506A1 (ko) |
JP (1) | JP2023522053A (ko) |
KR (1) | KR102415204B1 (ko) |
CN (1) | CN115916803A (ko) |
BR (1) | BR112022020836A2 (ko) |
CA (1) | CA3181812A1 (ko) |
MX (1) | MX2022012925A (ko) |
WO (1) | WO2021210924A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114058642A (zh) * | 2021-11-26 | 2022-02-18 | 中国农业科学院北京畜牧兽医研究所 | 表达非洲猪瘟病毒ep153r-ep402r蛋白的重组腺病毒及构建方法 |
CN114409742A (zh) * | 2021-12-27 | 2022-04-29 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟病毒p49蛋白抗原表位及其应用 |
CN114989266A (zh) * | 2022-06-16 | 2022-09-02 | 华中农业大学 | 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103805615A (zh) * | 2014-02-19 | 2014-05-21 | 孙洁 | 密码子优化的非洲猪瘟病毒p54基因、其核酸疫苗及应用 |
CN103172749B (zh) * | 2013-02-01 | 2014-10-08 | 广州谱泰生物技术有限公司 | 一种非洲猪瘟蛋白工程疫苗的制备 |
KR20160094674A (ko) * | 2015-02-02 | 2016-08-10 | 대한민국(농림축산식품부 농림축산검역본부장) | 아프리카 돼지열병 바이러스 단백질 k205r에 대한 단클론항체 및 이를 포함하는 아프리카 돼지열병 바이러스 진단용 조성물 |
WO2020060403A2 (en) * | 2018-09-18 | 2020-03-26 | Stichting Wageningen Research | African swine fever virus vaccine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302371B (zh) | 2019-08-21 | 2023-05-26 | 军事科学院军事医学研究院军事兽医研究所 | 灭活asfv作为复合疫苗的免疫攻毒保护成分的用途 |
-
2021
- 2021-04-14 JP JP2022562972A patent/JP2023522053A/ja active Pending
- 2021-04-14 EP EP21788370.1A patent/EP4137506A1/en active Pending
- 2021-04-14 CA CA3181812A patent/CA3181812A1/en active Pending
- 2021-04-14 WO PCT/KR2021/004724 patent/WO2021210924A1/ko unknown
- 2021-04-14 MX MX2022012925A patent/MX2022012925A/es unknown
- 2021-04-14 CN CN202180042721.7A patent/CN115916803A/zh active Pending
- 2021-04-14 BR BR112022020836A patent/BR112022020836A2/pt unknown
- 2021-04-14 KR KR1020210048852A patent/KR102415204B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103172749B (zh) * | 2013-02-01 | 2014-10-08 | 广州谱泰生物技术有限公司 | 一种非洲猪瘟蛋白工程疫苗的制备 |
CN103805615A (zh) * | 2014-02-19 | 2014-05-21 | 孙洁 | 密码子优化的非洲猪瘟病毒p54基因、其核酸疫苗及应用 |
KR20160094674A (ko) * | 2015-02-02 | 2016-08-10 | 대한민국(농림축산식품부 농림축산검역본부장) | 아프리카 돼지열병 바이러스 단백질 k205r에 대한 단클론항체 및 이를 포함하는 아프리카 돼지열병 바이러스 진단용 조성물 |
WO2020060403A2 (en) * | 2018-09-18 | 2020-03-26 | Stichting Wageningen Research | African swine fever virus vaccine |
Non-Patent Citations (4)
Title |
---|
"GenBan", Database accession no. KM609379 |
"GenBank", Database accession no. KJ380911 |
DATABASE NUCLEOTIDE 6 April 2014 (2014-04-06), ANONYMOUS : "African swine fever virus p30 (CP204L) gene, complete cds ", XP055858799, retrieved from NCBI Database accession no. KJ195684 * |
TAKAMATSU ET AL., VIRUS RES., vol. 173, no. 1, April 2013 (2013-04-01), pages 110 - 21 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114058642A (zh) * | 2021-11-26 | 2022-02-18 | 中国农业科学院北京畜牧兽医研究所 | 表达非洲猪瘟病毒ep153r-ep402r蛋白的重组腺病毒及构建方法 |
CN114409742A (zh) * | 2021-12-27 | 2022-04-29 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟病毒p49蛋白抗原表位及其应用 |
CN114989266A (zh) * | 2022-06-16 | 2022-09-02 | 华中农业大学 | 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用 |
CN114989266B (zh) * | 2022-06-16 | 2024-02-13 | 华中农业大学 | 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20210127887A (ko) | 2021-10-25 |
JP2023522053A (ja) | 2023-05-26 |
CA3181812A1 (en) | 2021-10-21 |
CN115916803A (zh) | 2023-04-04 |
EP4137506A1 (en) | 2023-02-22 |
MX2022012925A (es) | 2023-02-16 |
BR112022020836A2 (pt) | 2022-12-27 |
KR102415204B1 (ko) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021210924A1 (ko) | 아프리카돼지열병 백신 조성물 | |
CN106459931B (zh) | 减毒的非洲猪瘟病毒疫苗 | |
Strube et al. | A gE deleted infectious bovine rhinotracheitis marker vaccine for use in improved bovine herpesvirus 1 control programs | |
Agarwal et al. | Helicobacter pylori vaccine: from past to future | |
WO2018124393A1 (ko) | 브루셀라 균 주요 공통 항원을 발현하는 lps의 o-항원 결실 비병원성 살모넬라 균주를 포함하는 브루셀라증 예방 또는 치료용 백신 조성물 | |
US10682403B2 (en) | Multi-epitope DNA vaccine for heartwater | |
WO2011025344A2 (ko) | 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물 | |
KR101209141B1 (ko) | 독성약화된 토끼 믹소마바이러스를 기본으로 한모노파라뮤니티 유발인자 | |
WO2019235705A1 (en) | Vaccine composition comprising recombinant protein of staphylococcus aureus attenuated enterotoxin and cytotoxin | |
Johnson et al. | Virus-induced autoimmune demyelinating disease of the central nervous system | |
WO2022181897A1 (ko) | 코로나바이러스감염증-19(covid-19)에 대한 재조합 아데노바이러스 백신 및 이를 이용한 병용요법 | |
US11110132B2 (en) | Live attenuated parasitic vaccine | |
WO2022119384A1 (ko) | 결핵의 예방 또는 치료용 약학적 조성물 | |
WO2016013873A1 (ko) | Rv3112, MTBK 20620 또는 MTBK 24820 단백질을 포함하는 결핵 예방용 백신 조성물 | |
WO2018056528A2 (ko) | 인플루엔자 b 백신 | |
KR101393286B1 (ko) | 신규한 돼지생식기호흡기증후군 바이러스 및 그의 용도 | |
WO2023113094A1 (ko) | 면역원성이 증가된 코로나바이러스감염증-19 백신 조성물 | |
WO2019132569A1 (ko) | 구제역 바이러스 a형 백신 조성물 | |
WO2023085760A1 (ko) | 신규한 재조합 뉴캣슬바이러스벡터 및 이를 포함하는 백신 조성물 | |
WO2024085723A1 (ko) | SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도 | |
WO2023027562A1 (ko) | 신종 코로나바이러스 감염증 대응 예방 백신 조성물 | |
WO2024112115A1 (ko) | 구제역 바이러스 유사 입자 또는 나노입자 생산을 위한 재조합 발현 벡터 및 이를 이용한 백신 조성물 | |
WO2022220380A1 (ko) | 재조합 킬함 쥐 바이러스 제조 및 이의 용도 | |
WO2024025299A1 (ko) | 카탈레이스 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 대장균 균주 | |
McFarland et al. | Vaccination of mice and swine with a pseudorabies virus mutant lacking thymidine kinase activity. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21788370 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022562972 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022020836 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021788370 Country of ref document: EP Effective date: 20221114 |
|
ENP | Entry into the national phase |
Ref document number: 3181812 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 112022020836 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221014 |